Jun. 30 – Israeli cancer drug company CureTech has received FDA approval for a Phase II clinical trial for a third indication of its flagship product, an antibody that stimulates an anti-cancer immune response against several forms of cancer. The study, to be conducted at the University of Texas MD Anderson cancer center, will measure the efficacy of the company’s antibody in treatment of non-Hodgekin’s lymphoma. It will be given in conjunction with the widely used treatment Rituxin. CureTech’s drug is already in two other Phase II trials to study its effect on colorectal cancer and on hematological malignancies. CureTech is a unit of Clal Biotechnology Industries. It is working in collaboration with Teva Pharmaceutical Industries.